Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (68)

III-01Khaled Abduljalil

Predicting the Developmental PK/PD of Cyclosporine (CsA) in Paediatrics

Thursday 10:05-11:35

III-02

Pragmatic Approach for Interpreting Antiretroviral Drug Concentrations Based on a Systematic Review of Population Pharmacokinetic Studies

Thursday 10:05-11:35

III-03

Capecitabine: a pharmacokinetic model derived from its clinical use

Thursday 10:05-11:35

III-04Oskar Alskär

Using allometric scaling on an integrated glucose insulin model for humans to investigate anti-diabetics drug effects in rats.

Thursday 10:05-11:35

III-05Claire Ambery

Application of population dose-response and dose frequency in respiratory

Thursday 10:05-11:35

III-06

Mechanistic NSCLC vascular tumor model: insights to prognosis towards personalized medicine

Thursday 10:05-11:35

III-07Jacqueline Anderson

PKPD modelling of human chlorpyrifos poisoning

Thursday 10:05-11:35

III-08Eduardo Asín-Prieto

Population pharmacokinetics of piperacillin in critically ill patients undergoing continuous renal replacement therapies

Thursday 10:05-11:35

III-09

Log likelihood profile intervals for ED50

Thursday 10:05-11:35

III-10Daren Austin

A closed-form solution set-point model of treatment response in multiple diseases

Thursday 10:05-11:35

III-11Nicolas Azzopardi

Modelization of bevacizumab effect on number of episodes of epistaxis in Hereditary Haemorrhagic Telangiectasia (HHT)

Thursday 10:05-11:35

III-12

Model-based analysis of disease progression in pancreatic cancer based on registry data collected from the Surveillance, Epidemiology, and End Result (SEER) database

Thursday 10:05-11:35

III-13Francesco Bellanti

Deferiprone sampling optimisation in a pharmacokinetic bridging study including children with β-thalassaemia

Thursday 10:05-11:35

III-14Brendan Bender

A multicompartmental population PK model elucidating the complex disposition of trastuzumab emtansine (T-DM1): an antibody-drug conjugate for the treatment of HER2-positive cancer

Thursday 10:05-11:35

III-15Margherita Bennetts

Delta Method Application: Landmark Prediction and Confidence Interval for a Non-Linear Longitudinal Model

Thursday 10:05-11:35

III-16Aliénor Bergès

Development of a mechanistic PK/PD model to guide dose selection of a combined treatment for systemic amyloidosis

Thursday 10:05-11:35

III-17Tarjinder Sahota

A mechanistic PK/PD model to predict the pharmacological depletion of serum amyloid P component in healthy volunteers

Thursday 10:05-11:35

III-18Kirsten Bergmann

Comparing a mechanistic with an empirical approach to assess resistance development of antibacterials in vitro.

Thursday 10:05-11:35

III-19Julie Bertrand

Population Pharmacokinetic-Pharmacogenetic study of Efavirenz in combination with anti-TB treatment in HIV-Infected Cambodian Patients

Thursday 10:05-11:35

III-20Roberto Bizzotto

Glucose Homeostasis Modeling: Improvement of the Insulin Action Component

Thursday 10:05-11:35

III-21Marcus Björnsson

A population PK/PD model for bispectral index of the fast acting anesthetic AZD3043 in healthy volunteers

Thursday 10:05-11:35

III-22Michael Block

Physiological modeling of inter-individual variability: Combining PBPK modeling and Markov-Chain-Monte-Carlo approaches

Thursday 10:05-11:35

III-23Michael Bolger

GastroPlus PBPK/PD Model Applied to Estimating Dose for an Elderly Population in an Alzheimer’s Disease Clinical Trial

Thursday 10:05-11:35

III-24Irina Bondareva

Population Pharmacokinetics of Phenytoin Estimated from Repeated Therapeutic Drug Monitoring (TDM) Data of Epileptic Patients

Thursday 10:05-11:35

III-25Emma Bostrom

Modeling and Simulation of Pharmacokinetics and H3 Receptor Occupancy for Dose Setting in a Phase IIa Study

Thursday 10:05-11:35

III-26Salim Bouchene

Whole Body Physiologically-Based Pharmacokinetic Model of Colistin and Colistimethate sodium in Critically Ill Patients

Thursday 10:05-11:35

III-27Marion Bouillon-Pichault

Modeling of pain scores from a flexible titration study using an ordered categorical approaches

Thursday 10:05-11:35

III-28

Predicting in vivo drug response and synergistic combinations from three-dimensional tumour cell cultures

Thursday 10:05-11:35

III-29Margreke Brill

Population pharmacokinetic model for cefazolin in serum and subcutaneous adipose tissue in morbidly obese and normal weight patients

Thursday 10:05-11:35

III-30Thierry Buclin

Monitoring Blood Prostate-Specific Antigen (PSA) after Radical Prostatectomy

Thursday 10:05-11:35

III-31Núria Buil Bruna

Modeling evaluation of different in vitro experimental designs to characterise antitumor drug effect

Thursday 10:05-11:35

III-32Theresa Cain

A systems approach to predicting differences in pharmacological response to a CYP1A2 substrate, resulting from pharmacokinetic differences in non-smokers, passive smokers and heavy smokers

Thursday 10:05-11:35

III-33Sophie Callies

Sensitivity analysis to help the assessment of variance: application to Target Mediated Drug Disposition (TMDD) PK/PD model describing the effect of a monoclonal antibody (mAb) on a circadian biomarker.

Thursday 10:05-11:35

III-34Yu-Jung Cha

Population Pharmacokinetics of Etanercept in Healthy Korean Male Volunteers

Thursday 10:05-11:35

III-35Quentin Chalret du Rieu

Semi-mechanistic thrombocytopenia model of a new histone deacetylase inhibitor (HDACi) in development, with a drug-induced apoptosis of megakaryocytes.

Thursday 10:05-11:35

III-36Pascal Chanu

On the use of hemodynamics biomarkers to assess the benefit of high doses of sildenafil in some patients with pulmonary arterial hypertension (PAH)

Thursday 10:05-11:35

III-37Ayyappa Chaturvedula

Development of population pharmacokinetic model for Tenofovir using sparsely sampled subject data

Thursday 10:05-11:35

III-38Chao Chen

Quantifying the Effectiveness of Dose Personalisation by Simulation for a Drug with Moderate Pharmacokinetic Variability

Thursday 10:05-11:35

III-39Marylore Chenel

In vitro – in vivo correlation by population approach applied to modified-release forms with double-peak absorption

Thursday 10:05-11:35

III-40S. Y. Amy Cheung

An update on structural identifiability of parallel pharmacokinetic experiments viewed as constrained systems

Thursday 10:05-11:35

III-42Karina Blei

Development and evaluation of dynamical whole body Physiologically-based Models of the Circulation and the Renin-Angiotensin-Aldosterone system

Thursday 10:05-11:35

III-43

Evaluation of Tumor-Size Response Metrics to Predict Survival and Progression Free Survival in First-Line Metastatic Colorectal Cancer

Thursday 10:05-11:35

III-44Francois Combes

Prediction of precision of individual parameter estimates and of shrinkage via the Bayesian Fisher information matrix in non-linear mixed-effects models with application in pharmacokinetics

Thursday 10:05-11:35

III-45Emmanuelle Comets

Dealing with BQL data in normalised prediction distribution errors: a new version of the npde library for R

Thursday 10:05-11:35

III-46Damien Cronier

Population Pharmacokinetic Study of a New Humanized Anti-CD20 Monoclonal Antibody AME-133v (LY2469298) in Patients with Previously Treated Folicular Lymphoma.

Thursday 10:05-11:35

III-47Zeinab Daher Abdi

Joint model for longitudinal exposure to mycophenolic acid and rejection survival data in the first year after renal transplantation

Thursday 10:05-11:35

III-48Elyes Dahmane

The influence of CYP2D6 genetic polymorphism on tamoxifen and its active metabolite exposure in breast cancer patients: preliminary results from a prospective, open-label trial.

Thursday 10:05-11:35

III-49

Development and application of a mechanistic physiologically based pharmacokinetic model to assess oral drug bioavailability post bariatric surgery in morbidly obese patients

Thursday 10:05-11:35

III-50Ruben de Kanter

The impact of using the well-stirred liver model in PBPK modelling for high-clearance compounds

Thursday 10:05-11:35

III-51Giuseppe De Nicolao

PCA-based modelling in antidepressant trials: a pre-mechanistic approach

Thursday 10:05-11:35

III-52Ivan Demin

Posterior predictive check to assess similarity of systemic exposure profiles of an inhaled drug product pre- and post- manufacturing modification.

Thursday 10:05-11:35

III-53Paolo Denti

Population pharmacokinetics of ritonavir-boosted darunavir together with efavirenz in healthy volunteers

Thursday 10:05-11:35

III-54

Evaluation of CYP2D6 Phenotype-Guided Tamoxifen Dosing in European Female Breast Cancer Patients using a PBPK-Model

Thursday 10:05-11:35

III-55Christian Diestelhorst

A Physiologically-Based Pharmacokinetic Model for Busulfan

Thursday 10:05-11:35

III-56Nassim Djebli

Pharmacokinetic/pharmacodynamic (PK/PD) Analysis of Teriflunomide in Patients with Relapsing Forms of Multiple Sclerosis (RMS)

Thursday 10:05-11:35

III-57Jennifer Dong

Assessment of Mechanism of Action and Drug Effects in Early Signal of Efficacy Trials Using Integrated Glucose-Insulin Modeling: A Simulation-Estimation Approach

Thursday 10:05-11:35

III-58Pinky Dua

A Systems Pharmacology model of the nerve growth factor (NGF) pathway to aid drug discovery and development

Thursday 10:05-11:35

III-59Vivek Dua

Multi-objective Optimal Control of Non-Viral Gene Delivery

Thursday 10:05-11:35

III-60

Joint modelling of the placebo response and the dropout mechanism using clinical data from a trial performed in patients suffering from major depressive disorder

Thursday 10:05-11:35

III-61

Optimal two-stage design for a population pharmacokinetic study in children

Thursday 10:05-11:35

III-62Jeroen Elassaiss-Schaap

Pharmacokinetic-Pharmacodynamic Modelling & Simulation of Org 52186, a V3 antagonist, in Support of a Challenge Agent Trial Design with dDAVP

Thursday 10:05-11:35

III-63Farkad Ezzet

Power Calculation Based on Pharmacokinetic Sampling Designs of ELND005 in a Phase 3 Clinical Trial Design in Mild Alzheimer Disease Patients

Thursday 10:05-11:35

III-64Iñaki F. Trocóniz

Exploratory analysis to evaluate the relevance of different mechanism involved in a bivariate response target mediated disposition model characterizing the IL12 – IFNγ relationship.

Thursday 10:05-11:35

III-65Christine Falcoz

Population PKPD modeling of an anti-diabetic compound with a new mechanism of action in ob/ob mice to predict the human dose

Thursday 10:05-11:35

III-66Mathieu Felices

Dose Regimen Assessement For Oral Fexinidazole

Thursday 10:05-11:35

III-67Gregory Ferl

A mixed-effects simulation approach to quantifying the impact of missing pre-treatment baseline clinical DCE-MRI data on estimated population parameters

Thursday 10:05-11:35

III-68

A database of PK-PD parameters and information for the modelling of anti-cancer drug regimen and combinations

Thursday 10:05-11:35

III-69Martin Fink

Population pharmacokinetic analysis of robenacoxib in dogs with chronic osteoarthritis

Thursday 10:05-11:35